28Feb/14

Investigation Report on China Tacrolimus Market, 2009-2018 – The International News Magazine

Investigation Report on China Tacrolimus Market, 2009-2018
The International News Magazine
Reportstack has announced a new market research publication on Investigation Report on China Tacrolimus Market, 2009-2018. Tacrolimus, also named as “FK506” and “FR-900506”, was developed by Fujisawa Pharmaceutical Co., Ltd. (later became 

and more »

28Feb/14

China Tacrolimus Market Investigation Report 2018 Forecasts – The International News Magazine

China Tacrolimus Market Investigation Report 2018 Forecasts
The International News Magazine
Tacrolimus, also named as “FK506″ and “FR900506″, was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade 
Investigation Report on China Tacrolimus Market, 2009-2018PR Carbon (press release)

all 4 news articles »

28Feb/14

CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL … – The Herald | HeraldOnline.com (press release)

CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL
The Herald | HeraldOnline.com (press release)
Concomitant administration of NOXAFIL with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin inhibitors. Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy

and more »

28Feb/14

CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL(R … – Wall Street Journal

CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL(R
Wall Street Journal
Concomitant administration of NOXAFIL with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin inhibitors. Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy

and more »

28Feb/14

CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL … – Business Wire (press release)

CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL
Business Wire (press release)
Concomitant administration of NOXAFIL with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin inhibitors. Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy

and more »

26Feb/14

Transplant drugs may cause body to reject new lungs – Futurity: Research News


GPB

Transplant drugs may cause body to reject new lungs
Futurity: Research News
Researchers found mice were more likely to reject newly transplanted lungs if key immune cells were missing, a situation that simulates what happens when patients take immunosuppressive drugs. These “memory T cells” are primed to “remember” 
New clues found to preventing lung transplant rejectionWashington University in St. Louis News

all 45 news articles »